Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9320152 | 0.87 | ACHE (0.58) | ACHECA12CA1CA2CA7 | |
| SCHEMBL23200753 | 0.83 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4697541 | 0.81 | FABP4 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9320774 | 0.81 | ACHE (0.58) | ACHECA12CA1CA2CA7 | |
| SCHEMBL23200728 | 0.81 | ACHE (0.55) | ACHECA12CA1CA2CA7 | |
| SCHEMBL14394480 | 0.79 | ALDH1A1 (0.48) | ACHECA1CA2ALDH1A1MAPT | |
| SCHEMBL490689 | 0.78 | PTGS1 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9320700 | 0.77 | NFE2L2 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28553711 | 0.77 | MEN1 (0.47) | ALDH1A1MAPTNFE2L2KMT2AMEN1 | |
| SCHEMBL27819715 | 0.76 | CA12 (0.46) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12173018-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2021-07-01 | — | — | US | disclosed |
| EP-3802551-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112469725-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-0440887-B1 | Improvement in the total synthesis of Erbstatin analogs | ERBA CARLO SPA (IT) | 1994-01-26 | — | — | EP | disclosed |
| US-5130472-A | TOTAL SYNTHESIS OF ERBSTATIN ANALOGS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1992-07-14 | — | — | US | disclosed |
| EP-0440887-A1 | Improvement in the total synthesis of Erbstatin analogs | FARMITALIA CARLO ERBA S.r.l. (IT) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | ACHE 479/4885CA12 3028/4885CA1 3021/4885 |
| US-12173018-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | ACHE 479/4885CA12 3028/4885CA1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.